IceCure Medical (ICCM) Net Cash Flow (2020 - 2026)

IceCure Medical (ICCM) has reported Net Cash Flow for 7 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 620.03% year-over-year to $3.9 million in Q2 2026; TTM through Jun 2026 was $6.6 million, a 251.93% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 141.77% from the prior year.
• Net Cash Flow was $3.9 million for Q2 2026 at IceCure Medical, up from -$785000.0 in the prior quarter.
• Over five years, Net Cash Flow peaked at $11.1 million in Q4 2022 and troughed at -$18.1 million in Q1 2023.
• A 5-year average of -$742722.2 and a median of -$767000.0 in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 463.58% in 2023 and jumped 620.03% in 2026, its largest moves.
• Over 5 years, Net Cash Flow stood at $11.1 million in 2022, then slumped by 41.76% to $6.5 million in 2023, then tumbled by 147.86% to -$3.1 million in 2024, then soared by 219.19% to $3.7 million in 2025, then grew by 5.38% to $3.9 million in 2026.
• The last three Net Cash Flow figures came in at $3.9 million (Q2 2026), -$785000.0 (Q1 2026), and $3.7 million (Q4 2025), per Business Quant data.